Browsing Tag
ruxolitinib
5 posts
FDA extends deadline for Incyte’s Opzelura cream review in pediatric eczema following submission of new manufacturing data
Incyte (NASDAQ: INCY) faces FDA review delay for Opzelura® cream in children aged 2–11 with eczema, following CMC data submission. Decision now due September 2025.
Novartis announces takeover bid for MorphoSys AG to boost oncology pipeline
In a significant move within the pharmaceutical industry, Novartis has entered into an agreement to launch a voluntary…
Incyte’s Ruxolitinib Cream demonstrates promising efficacy in TRuE-AD3 study
Incyte (Nasdaq:INCY), an esteemed biopharmaceutical giant, has unveiled compelling expanded findings from its Phase 3 TRuE-AD3 study on…
Incyte bags Opzelura EC approval for treatment of non-segmental vitiligo
Incyte has secured marketing authorization for Opzelura (ruxolitinib) cream 15mg/g from the European Commission (EC) for non-segmental vitiligo…
US biopharma company Incyte bags Opzelura FDA approval for vitiligo
Opzelura FDA approval for vitiligo : Incyte has secured approval for Opzelura (ruxolitinib) cream 1.5% from the US…